(ANSA) - CHICAGO, June 06 - An unprecedented and "revolutionary intelligent chemotherapy" can be defined as the new therapy against Her2-low metastatic breast cancer with the so-called 'conjugated antibodies'.
To explain it, in a press conference at the Congress of the American Society of Clinical Oncology (ASCO), is Giusepe Curigliano, professor of medical oncology at the University of Milan and director of the Division for the development of new drugs and innovative therapies at the European Institute of Ioncology (Ieo).
The expert underlined, commenting on the study on the conjugated antibody trastuzumab-deruxtecan presented at the ASCO conference, is a "new therapy that will revolutionize the treatment for thousands of patients" with advanced breast cancer: "in fact, tens of thousands can benefit from it - he stressed - breast cancer patients with low Her2 protein expression (Her2-low), but also patients with triple negative breast cancer, particularly difficult to treat, always with low Her2 protein level ".
Now, Curigliano's invitation, "it will be very important to disseminate this information to ensure that the many patients who have an indication can access therapy, for now.
The conjugated antibody, explains the expert, "represents a new therapeutic frontier and acts as a sort of Troia horse: the antibody is in fact linked, 'conjugated' to the chemotherapy drug and, once in the organism, carries it directly inside the tumor cell. Hence the definition of intelligent chemotherapy, since the chemotherapy is administered in a targeted way into the tumor cell ".
(HANDLE).